Pamorelin 3.75 mg
- The treatment of locally advanced or metastatic, hormone-dependent prostate cancer
- As concomitant to and following radiotherapy in patients with high risk localized or locally advanced prostate cancer
- The treatment of endometriosis and for use in the context of in vitro fertilization programs
Triptorelin 3.75 mg
18 Years Old and Above
The recommended dose of Pamorelin 3.75 is 3.75 mg triptorelin (1 vial) administered once a month (4 weeks) as a single intramuscular injection.
Once reconstituted, the suspension of Pamorelin 3.75 mg should be intramuscularly injected relatively rapidly and in an uninterrrupted manner in order to avoid any potential blockage of the needle.
In high risk localized or locally advanced hormone-dependent prostate cancer:
Triptorelin as concomitant to and following radiation therapy, clinical data have shown that radiotherapy followed by 3 years of androgen deprivation therapy is preferable to radiotherapy followed by 6 months of androgen deprivation therapy. The treatment duration of androgen deprivation therapy recommended by medical guidances is 2-3 years in these patient populations receiving radiotherapy.
In women the treatment begins during the early follicular phase. The treatment of endometriosis should not exceed 6 months.
For use in the context of in vitro fertilization (IVF) programs:
Down-regulation in the context of medically assisted procreation (IVF, GIFT) or induction of follicular maturation during non-assisted treatments, etc.: one deep intramuscular injection of triptorelin administered on the second day of the cycle.
The stimulation by gonadotropins should be performed when the plasma levels of estrogens are less than 50 pg/ml (usually around the 15th day of the cycle).